Clinical Trials

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06909825 2026-04-08

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

85 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT04884360 2026-03-02

MONO-OLA1

366 enrolled

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT02264678 2026-02-20

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

357 enrolled

Ovarian Neoplasms

NCT03742895 2026-02-18

MK-7339-002

326 enrolled

Advanced Solid Neoplasms

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 2 FDA

Breast Neoplasms

NCT03775486 2026-02-10

ORION

401 enrolled 26 charts

Non-small Cell Lung Cancer NSCLC

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT03459846 2026-01-30

BAYOU

154 enrolled 13 charts

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 2 FDA

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

197 enrolled

Other solid neoplasm

Solid Tumors

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

117 enrolled

Muscle Invasive Bladder Cancer

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 2 FDA

Endometrial Neoplasms

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 2 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT03334617 2025-10-27

HUDSON

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05898399 2025-10-15

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

220 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04380636 2025-08-17

MK-7339-012

870 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

327 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT04624204 2025-07-02

MK 7339-013

672 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05498155 2025-06-10

OlympiaN

50 enrolled

Breast Neoplasms

NCT04123366 2025-03-17

MK-7339-007

300 enrolled

Other solid neoplasm

Solid Tumors

NCT03737643 2025-01-29

DUO-O

1,407 enrolled 3 FDA